Greetings. Welcome to TG Therapeutics' second quarter conference call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, I'll turn the conference over to Jenna Bosco, Chief Communications Officer. Thank you. You may begin.

Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics' second quarter 2026 financial results are Michael Weiss, our Chairman and Chief Executive Officer, Adam Waldman, our Chief Commercial Officer, and Sean Power, our Chief Financial Officer. Following our Safe Harbor Statement, Mike will begin with an overview of our recent corporate developments, Adam will provide an update on our commercial efforts, and Sean will review our financial results before we open the call for Q&A. Before we begin, I would like to remind everyone that today's discussion will include forward listen statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include expectations regarding our future operating and financial performance, including sales trends, revenue guidance, projected milestones, development plans, and outlook for our marketed product and pipeline products. Please note that these statements are subject to risks and uncertainties that can cause our actual results to differ materially from those indicated. These risks are detailed in our SEC filings. Additionally, any forward-looking statements made today reflect our views only as of this date, and we disclaim any obligation to update or revise them. As a reminder, this conference call is being recorded and will be available for replay for the next 30 days on our website at www.tgtherapeutics.com. With that, I will turn the call over to Mike Weiss, our CEO.

Thank you, Jenna, and good morning, everyone. We appreciate you joining us. The second quarter of 2026 was another quarter of strong execution. More importantly, it marked an important evolution for TG Therapeutics. For the last several years, we've been fingerly focused on one objective, establishing pre-omphi as a leading therapy in relapsing multiple sclerosis. That remains our highest priority today and will remain so for years to come. But increasingly, Reunbi has enabled us to build something much bigger. It really represents the starting line for TG, the starting line for continued innovation, from new formulations and new indications to novel therapeutic approaches to thoughtful business development, and ultimately, for building an organization capable of repeatedly creating value for patients and shareholders. The second quarter provided a window into where we're headed. From a commercial perspective, we delivered another excellent quarter, once again exceeding our guidance. New patient starts continue to grow, physician adoption expanded, and our commercial organization continue to execute at an exceptionally high level. As we approach a billion-dollar annualized run rate, we continue to believe we're still early in the lifecycle of the Breonby franchise. Our objective is straightforward, to become the number one prescribed anti-CD20 therapy in relapsing MS based on dynamic market share. And we're making meaningful progress toward that goal, not only by continued commercial execution, but also by ongoing product innovation and a growing body of real-world evidence demonstrating the BrioMV value proposition. During the quarter, we announced positive top-line phase three results from our enhanced study, demonstrating that patients can initiate Briambi with a single 600 milligram infusion, replacing the currently approved day one and day 15 initiation schedule. Based on feedback from healthcare providers, the ability to initiate Briambi with a single infusion will be viewed very positively by both patient and infusion centers. Eliminating the need for an additional infusion visit reduces treatment burden and removes one of the barriers to switching from another anti-CD20 therapy to Briombi. If all goes well, this new initiation schedule could be available as early as the middle of next year. We also reported additional real-world data from our ongoing enabled phase score study demonstrating significant and durable improvements in patient-reported outcomes on Bri-Ombi. Importantly, patients transitioning from prior anti-CD20 therapies maintain strong disease control while also reporting meaningful improvements in convenience, tolerability, and overall treatment satisfaction. While we continue to strengthen our position within the IV anti-CD20 market, we also made significant progress during the quarter advancing subcutaneous lituximab, the active agent embryonzi. We reported positive phase one bioavailability data for our proprietary subcutaneous formulation, increasing our confidence in the quarterly dosing schedule that is being evaluated in our fully enrolled phase three study. We're expecting top line phase three results around year end or early next year. And to be clear, subcutaneous ReomV is not simply another formulation. It has the potential to materially expand the reach of the franchise. Today, we participate in the physician administered segment representing approximately 60 to 65% of the overall anti-CD20 market. A successful subcube ReomV will allow us to compete for patients who choose a self-administered therapy, giving us the opportunity to participate across the entire anti-CD20 landscape for RMS. When pricing dynamics are considered, the sub-Q opportunity has the potential to more than double Breonvy's current addressable market. And when you combine the strength we're already seeing in the Ivy franchise with the potential to have a best-in-class subcutaneous product, we continue to believe the long-term opportunity for the Breonvy franchise is substantially greater than many appreciate today. Beyond MS, we've begun extending the reach of Riombe into additional autoimmune mediated diseases. During the quarter, we announced encouraging preliminary phase one data in patients with myasthenia gravis and initiated what we believe could be a registration-directed phase two study. There are now multiple treatment options available for MG, but our approach, combining the rapid symptomatic relief of FCRN inhibition with the The possibility for durable disease control with Brumby has the potential to represent a meaningful treatment advance by reducing the long-term treatment burden of FCRN inhibition and optimizing disease control. We also initiated a phase two study in treatment resistant schizophrenia. Growing evidence suggests that a subset of treatment resistant patients may have an underlying autoimmune component to their disease. Our study is designed not only to evaluate clinical outcomes, but also to better characterize that biology through biomarker analysis. The current investment is modest, but the potential upside, if the biology proves correct, could be significant. And we continue to evaluate additional opportunities to expand BreaumV. Finally, I'd like to discuss Azercel, our allogeneic CD19 CAR-T program. We continue to make encouraging progress. We have now enrolled more than 20 patients, primarily with progressive forms of multiple sclerosis, and recently expanded the study to include additional B cell mediated diseases. While we're focused on generating rigorous clinical evidence before drawing conclusions, we've been encouraged by the continued enthusiasm from investigators, drawn patient interest, and the anecdotal reports emerging from some study participants. We're looking forward to sharing a clinical update during the second half of the year. When I step back and look at everything we accomplished during the quarter, continued commercial execution, positive enhanced data, growing real-world evidence from Enable, encouraging progress with sub-Q, expansion into MG and schizophrenia, and continued advancement of Azercel, I see a strategy coming to life. One successful product becoming a durable engine for innovation. Our goal isn't simply to build a great product, it's to build an organization that repeatedly creates great products for patients and great opportunities for our shareholders. Before turning the call over to Adam, let me briefly touch on our capital allocation. Our philosophy remains unchanged. We will continue to invest where we believe we can create the greatest long-term value. That means, first and foremost, investing behind Briomdi and our commercial efforts. Also, advancing our pipeline and pursuing strategic business development opportunities that strengthen our long-term vision and generate attractive returns. As well as when appropriate, continuing to repurchase our own shares. Every capital allocation decision begins with the same question. Where can we create the greatest value for dollar invested? That discipline has served us well and will continue to guide us. With that, I'll turn the caller to Adam Wallman, our Chief Commercial Officer. Adam, please go ahead.

Thanks, Mike, and good morning, everyone. I'm delighted to provide a commercial update. Performance was once again very strong. Second quarter was another record quarter of new patient starts, which surpassed our prior records even in the first quarter. Persistence continues to exceed our expectations. We're adding new prescribers. Repeat prescribers continue to increase. And importantly, an increasing percentage of patients are beginning their treatment journey with Breon-V rather than switching to us later. We highlighted that trend last quarter as one of the strongest leading indicators of long-term franchise strength. The second quarter reinforced that view. When you combine a growing installed base, record new patient demand, strong persistence, and expanding physician adoption, you create a business that becomes more durable and more predictable over time. And that's exactly what we're seeing in our business today with another excellent quarter. We generated approximately $228 million in U.S. Briandti net product revenue, with global revenue exceeding $240 million, once again exceeding our guidance. In the U.S., that represented quarter-over-quarter growth of approximately 17%, and year-over-year growth of more than 64%. Based on the strengths of the business, we're raising our full-year U.S. Briandti net revenue guidance to $890 million to $905 million, and now expect approximately $950 million in total global revenue for 2026. Looking to the balance of the year, we expect the fourth quarter to drive second-half growth, positioning us to exit 2026 with quarterly U.S. net revenue exceeding $250 million, our first billion-dollar annualized revenue run rate, and setting the stage for our first billion-dollar-plus U.S. BreaMD revenue year in 2027. Building a blockbuster brand in less than four years doesn't happen by accident. It's the result of disciplined execution and relentless focus on the fundamentals that matter most. Over the past several years, we've built a commercial platform designed not simply to launch a product, but to support a long-duration franchise. Our field organization, market access capabilities, patient support services, and direct-to-consumer investments continue to make Brionby easier to prescribe, easier to access, and easier to remain on. We've also been encouraged by the early response to our direct-to-consumer campaign and plan to expand those efforts during the second half of the year. We believe increasing patient awareness complements the commercial infrastructure we've built and represents another important driver of long-term growth. As the business continues to grow, we're able to leverage that commercial platform across an expanding franchise, creating increasing operating leverage over time. Looking ahead, we see two important opportunities to build on our MS franchise. The first is a new simplified IV initiation schedule supported by the positive enhanced phase three results. If approved, initiating patients with a 600 milligram infusion further enhances an already strong IV offering, and we believe it will fuel additional share gains within the IV marketplace. It reduces complexity for physicians, for infusion centers, and most importantly, for patients. The second opportunity is sub-Q Briumbi. Today, approximately 35 to 40% of the dynamic anti-CD20 market consists of patients receiving self-administered therapy, a segment where we don't currently participate. A successful sub-Q Briumbi program would allow us to compete directly in that segment with what we believe could be a highly differentiated product. But the more important point is how we think about these opportunities together. While they are two products, they will represent one franchise, powered by the trusted efficacy and safety profile of Breambi, that HCPs have already prescribed to more than 30,000 patients globally today. Our goal isn't to ask physicians or patients to choose between IV and sub-Q. Our goal would be to ensure whichever route of administration best fits an individual patient's need, there's a compelling Breambi option. That allows us to compete across the entire anti-CD20 RMS market with a single trusted brand supported by one commercial organization, one reimbursement infrastructure, one patient support platform, and one field team. That's powerful. And it's another example of how the operating leverage of this business continues to improve over time. When you step back and consider the size of the IV market, the portion of the market will be able to access with sub-Q. the trajectory we're seeing today and the commercial infrastructure we've already built, it's easy to see why the long-term opportunity for the Breambi franchise is substantially larger than where it sits today and reinforces the confidence that Breambi has the potential to become the leading therapeutic in this category over time. We're building that opportunity on top of a patent estate extending into the 2040s. That gives us confidence to continue investing in the brand, investing in lifecycle innovation, and investing in the commercial platform because we believe those investments will continue generating value for many years to come. So when I look at the business today, I don't see just another strong quarter. I see a commercial franchise that's becoming stronger, expanding its patient base, deepening physician adoption, demonstrating strong persistence, and creating increasing operating leverage. That's why we remain confident that we're still in the early innings of realizing Brienne's full potential. With that, I'll turn the call over to Sean.

Thanks, Adam. A lot of what you just heard from Mike and Adam shows up in the financials. Let me take you through the details. U.S. net product revenue in Q2 was approximately $228 million. up 64% versus the same quarter last year. Total of that product revenue was $236 million when including product sales to our ex-U.S. partner. Add in $4.5 million of license, royalty, and other revenue, and total revenue for the quarter was $240 million. In terms of margin, the gross margin of our U.S. business remains remarkably consistent and predictable at approximately 87%. When factoring in sales to our ex-US partner and other revenue sources, total gross margin landed at 83% for the quarter in line with our expectations. On the expense side, OPEX, which we define as R&D and SG&A, excluding stock-based compensation, was approximately $150 million for the quarter, including roughly 55 million of charges associated with subcutaneous and secondary source manufacturing activities. Excluding those, underlying OPEX was about 95 million, consistent with our expectations and down from Q1. As a reminder, our 2026 OPEX projections include approximately 100 million for these manufacturing activities. We call those costs out separately because they are expense through R&D as incurred, and while not all of it converts to saleable inventory, a meaningful portion does, which would represent a gross margin tailwind in future periods if the programs are successful. The result was operating income of 21.7 million for the quarter and net income of 7.8 million or 5 cents per diluted share. Excluding the manufacturing charges I referenced earlier, operating income would have been approximately $76 million, a meaningful step up from both Q1 and the prior year period. On the same basis, net income comes to approximately $62 million, and that's the number we'd point you to as the better reflection of our underlying earnings power. Turning to the balance sheet, we ended the quarter was approximately $612 million in cash, cash equivalents, and investment securities. On revenue guidance, U.S. pre-MV net revenue through the first half was approximately $423 million, on track for our full-year target of $890 to $905 million. Total revenue of approximately $445 million puts us equally well positioned against our $950 million full year global target. In terms of expenses, we expect full year OPEX of $350 to $400 million, excluding stock-based compensation, reflecting continued investment in our commercial organization and expanded DTC efforts. On top of that, we expect approximately $100 million for the manufacturing-related expenses I referenced earlier. All in, it was another strong quarter financially, and as Mike and Adam have laid out, we believe the best is still ahead of us. With that, I'll now turn the call back over to the conference operator to begin the Q&A.

Thank you. We'll now be conducting a question and answer session. If you'd like to ask a question at this time, you may press star 1 from your telephone keypad, and a confirmation tone will indicate your lines in the question queue. You may press star 2 if you'd like to withdraw your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment for our first question, please. Thank you. And the first question today comes from the line of Tara Bancroft with C.D. Cowan. This is your third question.

Hey, good morning. This is Greg Torazon for Tara. Thanks for taking our question. So as you evaluate the long-term opportunity for subcube pre-on B, How different are your peak sales assumptions under a quarterly dosing regimen versus a more frequent every two-month regimen? Thanks for the question. Adam, you want to take that one?

Yeah, I mean, we haven't given – thanks for the question, Greg. We haven't given specific guidance on that in terms of revenue, but in general, we do think a less frequent dose is going to be better than a more frequent dose.

Thank you. The next question is from the line of Prekar Agarwal with Cantor for Cheryl. Please just use your questions.

Hi, congrats on the quarter, and thanks for taking my questions. Maybe firstly on the subcute brand, since this would be a Pardew product, just curious how you'll approach the pricing here and contracting compared to Casimta, since you could have a quarterly regimen here. And any sort of initial comments on how do you think the update will be, given the brand familiarity here? And maybe just a couple of clarifications. On the OPEX increase, if you can elaborate on how much of that is driven by R&D, given some of the pipeline investments versus SG&A. And then a clarification on the BNB sales that you provide to Nurex Pharma, XUS seems like a meaningful increase in $25 million for the guide. Are there some one-offs here to Nurex Pharma for this year for XUS buildup, or are you expecting more meaningful royalty contribution from XUS given this increase in XUS supply? And just to clarify if the sales to Nurex Pharma is done at a cost plus a markup on the revenue line item. Thank you so much.

Proctor, thank you for that five-part question. We'll try to break that down. Adam, do you want to start us off with some thoughts on sub-Q, part D, pricing and contracting and potential uptake?

Sure. Yeah, thanks for the question, Proctor. You know, on the sub-Q side, we're not going to talk about pricing yet. We've still got a little bit of time here. We'll do the work that we need to do. But we do think we can price it competitively in the market and we'll take into account all the different factors you need to take into account. As far as uptake, you know, we feel really good about the profile of the drug. We think the uptake will be strong. You know, we continue to do market research and we'll continue to do more as we get closer to launch here. But, you know, the profile that we have in mind, we think will do quite well in the space.

Yeah, I'll just layer on top of that, you know, Adam and the team do, you know, proper market research. I do my own work when I go out on the field. I've been out in the field probably six or seven days in the last 21 days meeting with clinicians at primarily academic, large academic centers. And I can tell you the enthusiasm and excitement for the SLEF-Q product is pretty incredible, actually, are pretty impressive. Particularly, it's really interesting. Most of the people have heard about what we're doing, so the pre-educated teams have been out there. They see the data online and wherever. But people who haven't yet realized that we're targeting a quarterly product that's in an auto-injector, their eyes light up. I think everyone is somehow thinking that you can't do this kind of a thing with, you know, taking IV to a sub-Q, and, yeah, it's really interesting to see how excited they get. So, like I said, Adam's doing the market research on the uptake properly, but I can tell you anecdotally, out in the field, when I talk to folks, they're pretty enthusiastic about it, and all there on top of that, they're also super excited about the enhancements through the consolidated dosing. I think that's something that's also going to be pretty interesting and how that impacts the uptake next year. All right, the part two of your question, OpEx drivers, slightly guidance, a little higher on the OpEx for the year. Sean, you want to take a crack at the distribution there, R&D, SG&A, and to your point, yes, we've extended R&D, but we're also – I'll layer in, and then, Sean, you can add a top. We've also, you know, Adam's team has done a really nice job piloting some DTC campaigns, and I think we're going to lean into some of that both on the commercial side but also online.

So I think you'll see some of that showing up, but Sean, maybe what else can you add Yeah, I think you covered it on the SG&A side, Mike, and of course, Parker, as you We know we call out the 100 million in subcontracting manufacturing, secondary source manufacturing costs as well, so we factor that into overall guidance as well. But I think the combination of those two things should cover it. I think your last question was on NXP X-RAS revenue for the rest of the year. So we do model in some continued product revenue, as you noted, that we've seen throughout the first half of the year. And then there is some other, of course, license and milestones related revenue that we model in for the remainder of the year, which drives that overall global revenue guide. Yeah, I'll just lay on top.

Yeah, I'll just lay on top. But they are moving along pretty well on driving revenues, and so royalties are picking up a bit. But, yeah, in the second half, it's probably more related to milestones and other payments at the lowest.

Thank you. I appreciate it. Thanks, Parker.

Our next questions are from the line of Michael DeFiori with Evercore ISI. Please receive their questions.

Hey, guys. Thanks so much for taking my questions, too, from me. Roche recently said that anti-CD20 competition was running above expectations and moved Ocrevus growth to the end of its range, to the low end of its range. Are you seeing acceleration in Breyambi's share gains and is that coming more from Ocrevus switches or treatment-naive starts? And my second question is related to the schizophrenia study. What result would you consider strong enough to justify a larger randomized study? And, yeah, I'll just leave it there.

So, Adam, maybe you can take the Roche anti-CB20 competitive issues that they're facing in the marketplace, which I assume was referring to us, which is interesting because people, I guess, didn't really think we could compete with Roche, but apparently they do believe so. Adam, I want to take that, and I'll take this against a question second.

Yeah, thanks for the question. You know, listen, this is certainly a competitive market space, and we've competed alongside the new product from a new formulation from Roche for several quarters, and we continue to grow our new patient business two record quarters in a row. So we continue to grow through the increased competition. And in terms of your question of where we're seeing it, we're seeing it from both switches from Ocrevus and treatment naive patient. And as I mentioned in our prepared remarks, I think the growth in naive patients reflects, you know, increasing physicians' confidence in the brand and starting with Briambi, which we see as a really important indicator of long-term share growth and confidence in the brand. And then importantly, from switching from Ocrevus, you know, we do know that they're encouraging switches from their IV version to their sub-Q version. But despite that, we're still continuing to see strength in patients switching over from Ocrevus to Briandvi. And we do see, you know, I think a lot of their business is coming from that switching as opposed to coming from Briandvi itself.

Yeah. Thank you, Adam, for that. I appreciate that. In terms of schizophrenia and the results that we would like to see to move on to phase three. So, Michael, the study is designed, we took a page out of our old oncology playbook. So it's designed as a Fleming two-stage design. So, you know, you basically assume that there's a certain placebo rate that we've derived from the literature and that a good drug would have a certain rate of response, a PANS response. And we compare those two in two steps to see if you can sort of reach the hurdle. If we reach the hurdle, rate of responders, again, as its design is set up against a historical placebo rate, you've got to get above a certain hurdle, then I think we'd be pretty confident to move forward. If we're below that, obviously, we'll look at the data and see, again, this is where biomarkers might come in to be helpful. And if the biomarkers are saying there's a subgroup, that makes more sense. We could then probably more likely rerun the smaller kind of study, the Flemming two-stage design on that, and confirm that that is predictive or not. But at the end of the day, you know, this is a design that can move very quickly, give us some really robust preliminary information, and give us an opportunity to move forward. So we'll keep you posted, but the ideal is, you know, we'll get the response rate that we're expecting from the broader population that we're studying. We'll use – again, we're doing the bioanalysis to check and see what, you know, what else is possible and what we can learn from it. But the main driver is going to be the response rate that we get.

Thank you. The next questions are from the line of Emily Bodnar with H.E. Wainwright. Please receive your questions.

Hi, good morning. Thanks for taking the question. I guess two for me as well. It looks like in the second quarter, majority of growth in the MS market is kind of coming from the subcutaneous side, so curious as you kind of advance and eventually commercialize free-on-base subcutaneous how you see the IV market growing past that point and then secondly you mentioned you've started some new indications for the Azure Cell trials besides MS can you clarify which those are? Thank you.

Sure Adam you want to talk about sub-q growth over time and how that impacts IV growth in the future?

Sure I mean look we our plan is to give people choice given we'll have an option in both markets we believe these are fundamentally two different markets, a physician-administered market and a self-administered market. Today, we compete in the IV space, and the sub-cube will provide us the opportunity to expand into the self-administered market, and that will substantially increase our market. Strategically, we think about it as one ground beef franchise, and I think different patients will have different preferences per route of administration, but our objective is to have a compelling brand, the option, regardless of which approach best fits in individual patients, which allows us, obviously, to compete across the entire RMS space with one trusted brand and all the things that I said, and we think that's a significant competitive advantage for the franchise overall.

Yeah, I'll put an exclamation point on that. I mean, we are fully committed to supporting our IV brand as we move forward, creating a sub-queue is about patient empowerment, patient choice. We want to show up where the patients want to be, and we want to make sure everyone has a brand of the option. But, you know, we don't know exactly where the market is going over time. Sub-queue, you know, the sub-queue distribution does oscillate quarter to quarter. Sometimes it's 30 percent, sometimes it's 35 percent, and we don't know if it's going to break down and become something different over time, but either way, we want to be prepared to make sure that patients have a choice. As for your AcerCell question, we expanded the study into relapsing MS, MG, CIDP, and NMO.

Great, thank you.

Thank you, Emily. The next question is from the line of Brian Chang with J.P. Morgan. Please use your questions.

Yeah, thanks for our Q&A question this morning, and congrats on the quarter. Maybe just first, can you give us a bit more color around your updated U.S. net product revenue guidance? How is the race reflective of your latest thinking of the IV uptick for the rest of the year? And then secondly, on MG, it would be great to hear how you're thinking about the opportunity here based on the post-FAR induction setting that you're aiming for in the trial. What are some of the patient characteristics that you expect to capture in a study that may ultimately differentiate yourself from other historical MG trials?

Thank you. Adam, you want to take a crack at the first part of that question on the guidance?

Sure, yeah, you know, first of all, we're excited about the second half of the year and raising our annual guidance again for the second time this year, so that's great. I think the best way to think about it, about the second half, is exactly how we outlined it in our prepared remarks. We continue to expect the fourth quarter to be the driver of the second half growth. And, again, we've raised the annual guidance here based on the strength of what we've seen in the first half with the fundamentals that we're seeing good progress in. Record new patient starts, excellent persistence, and continued physician expansion. All of that is giving us the confidence to raise here, and we feel good about the full-year trajectory.

Yeah, and again, I'll just put an exclamation point on that. I think during the course of the year, we've already raised our guidance somewhere in the order of $75-plus million. So we're going to continue to drive, and we're looking forward to, you know, our end of year coming out at the next velocity of, you know, a billion-dollar run rate, which we think is pretty impressive. I know I haven't discussed it in the script, so I won't say more about that. On the MG and how we're thinking about it, you know, MG is becoming a better-served marketplace. But if you look at, you know, how the treatments are delivered today, it's, you know, my words, maybe not others, but it's a little clunky. You basically put a person into a really good symptomatic place relatively quickly using FCRN addition, and then you wait and let the symptoms come back, and then you treat again. And it's a pretty intensive program. I mean, it's not the worst schedule once a week or every other week or whatever they're doing and they're improving upon. But it's still a little, you know, definitely a treatment burden involved with that. The idea here is we can, you know, leverage that kind of rapid symptomatic relief of FTR inhibition and hopefully layer in the long-term, you know, durability of response with something like Briandie. And, you know, put the two pieces together, and hopefully you have a treatment that is really tailor-made for this kind of a population, get them into a symptomatic remission quickly, keep them there by using Vryonzi, whether it's every six months or quarterly. I think quarterly will be a really nice option for patients to be able to do it at home and really would simplify, I believe, the treatment burden. So, yeah, we think there's room for improvement, and any time there's room for improvement, you know, there's an opportunity.

Questions from the line of William Wood with B-Violet Securities. Please receive your questions.

Thanks very much for taking our questions, and congrats on a very nice quarter. When we're thinking about sort of the second half in the year-end guidance, your fourth quarter or your $1 billion exit runway implies a fourth quarter of around $250 million, which leaves third quarter relatively flat. You know, so how should we sort of think about what may be driving that third quarter decrease or flatness maybe, seasonality or growth to net or potentially channel changes? And then, you know, coming away from fourth quarter and looking towards potentially into 2027, how should we think about the growth trajectory into 2027 and, you know, how do we start to think about the more meaningful focus of, I guess, TG a little bit more broadly? You know, is it RE-OMV, IV, or is this sort of the addition of the sub-Q coming to market? Thanks.

Yeah, I'll leave off at the second half of that question. I'll let Adam take some part of that first question, but obviously, we haven't given guidance yet for 2027, so we'll do that hopefully early next year, as we've done in past years, but we're certainly feeling good about where we're heading. And in terms of, you know, the overall franchise, we think that we have multiple pieces that will continue to drive growth. We've got next year, ideally, we'll have enhanced growth. with the consolidated dosing, which should hopefully give us another growth expansion. And then sub-Q is an order of magnitude change, right? We're talking about something that is of size comparable to the current market, if not larger than the current market that we're currently serving. And the current market we're serving, we're not even close, in our belief, to full saturation of our market share. So, 27, I think, is going to be a really exciting year for us. Like I said, with the launch, hopefully sometime in the middle of the year, we could see some really interesting share gains. And then, you know, once we get into 28 sub-queue, it's a whole other ballgame. So I think we're not there yet to give any guidance for 2027, but I think we're in a great place leading into that. Adam, any thoughts on Q3, Q4 dynamics?

Sure, yeah. Listen, we've talked about this before on the call, and certainly as we move across the year, each quarter has some unique dynamics with Q3 having some seasonal dynamics at play, not just for Briambi, but the entire MS market. It was simply too early in the quarter to know exactly how it would land. I think what we have is greater visibility and confidence is the second half in aggregate, and that's why we felt comfortable raising the full-year guidance, how exactly it plays out between quarters is not much of our concern. We don't concern ourselves too much about it. We're more focused on the full-year guidance. And, you know, as I said, I think the best way to think about the second half is how we outlined it, where we continue to expect fourth quarter to be the driver of the second half growth.

Got it. Appreciate that.

Next question is from the line of Chacha Yang with Jeffries. Thanks for seeing us your questions.

Hi, Gene. This is Chacha on for Roger. Thanks so much for taking your questions, and congrats on another great quarter. I have two questions here from us. One is whether you can speak more to your plans for your DTC campaign expansion and what we can expect to see from that going forward. And then two is you talked about persistence being longer than you expected, whether you can talk more about what's driving that.

Adam, I think this is all you.

Yeah, sure. Thanks for the question, Chacha. So, you know, as I said in my remarks, I think the responses to what we have done so far in the DTC arena has been positive. All the leading indicators have been trending in the right direction. It gives us confidence to expand it here. You know, you can expect, you know, more of an omni-channel presence across, you know, digital, linear television, connected television, social channels, and sort of putting a full complement of assets in the market. And, again, we're excited about it. And the leading indicators so far give us the confidence to continue to do that. And then as far as your question on persistence, yeah, I mean, we continue to see really good persistence here and continues to be better than what we've expected. You know, we think that these patterns are basically driven that when patients do well, they stay on therapy. So we think it's a, you know, a sign of confidence in Breambi, and, you know, we'll continue to track it. We're still relatively early in the life cycle of this brand, but so far we're very encouraged by the persistence trends that we continue to see.

Great. Thank you for that.

Our next question is from the line of Perkar Agarwal with Cantor Fitzgerald. please just use your question.

Thanks for squeezing me again. Had a lot of questions this quarter, Mike. Firstly, on growth to net, if you can just comment on the growth net for the quarter, I think you have previously said 65% of how did it track related to your expectations and how should we think about growth to net for the rest of the year? And secondly, we're seeing some consolidation happening in the mid-cap biotech space. You have, you know, predictability around cash flows, especially meaningful cash flows starting next year. What's the appetite for doing something meaningful on the BD front, or are you looking at more opportunities more on the earlier side? Thank you so much.

Adam or Sean want to talk about the GCN for the remainder of the year?

Sure, yeah, gross net is basically unchanged from what we said. We predicted to be in the mid-60s, and that prediction is still accurate.

And more on the biz dev side, strategic side, Procker, you know, our goal is always to maximize shareholder value. As I said in our discussion on capital allocation, you know, we continue to ask the question every day, what is the best use of our money? How can we best invest it? To me, obviously, it's an interesting part of the business. it's, you know, from my prior years as a hedge fund manager, I get to really think about the best way to create value for shareholders. As everyone knows, I'm one of the largest single shareholders, so I do care about how we spend our money and how we invest it. And, yeah, I think we're building a company that we do think has predictable cash flow and growing and will be growing for quite some time. and we have patents out to the mid-2040s, so I think the durability of this franchise is far beyond what most people, I think, on the sell side are modeling today, and I think that probably should be adjusted. All that along with saying we're going to continue to build a company that's free shareholder value. We're going to continue to look for opportunities out there. We're not looking for any major consolidation plays. I think we continue to look for, on our side, on the inbound side, we look for things that will create value without stressing our bank accounts. We think that there are a lot of interesting single assets, or potentially even small companies, but mostly single assets that we can add to the company. One of the things we would like to think about is, you know, wherever BRYOM-V can go next and AcerCell can follow, we'd like to think about what are the pieces we could put together in those areas. So, as we continue to build out into some of these new therapeutic indications, the lead will always be around where can BRYOM-V work, where can AcerCell work, because there's a lot of overlap between those two. and then are there other mechanisms of action within those therapeutic areas that could be applied to satisfy the needs of that patient population? So that's why I think we're thinking about it. But again, our goal is always to create and maximize long-term shareholder value. We understand that when we do that, we, of course, will create the most opportunities for us and our shareholders.

Thank you. At this time, we've reached the end of our question and answer session. I'll hand the floor back to Mike Weiss for closing comments.

And thanks, everyone, for joining us. Just a quick summary on the 2Q progress. I think we did a – we didn't really have another really strong quarter. We generated positive Phase III data from the enhanced trial. We advanced our sub-Q BRYOMB toward a pivotal readout later this year or early next. We expanded BRYOMB into new autoimmunity-mediated diseases. We continue to advance Asia Sale. And as you heard from Adam, we've raised our guidance to $890 to $905 million just in the U.S. alone and globally approaching $950 million. We continue to see Brionby as a multi-billion dollar franchise in the making. I can't emphasize that enough. Creating value for our shareholders is our top priority. And, you know, Burundi, as we said, becomes really the beginning of what we're working on to create value, becomes the lead of everything that we focus on. And finally, I just want to thank our shareholders for their continued support, our employees for their commitment to our mission, and the patients, of course, who we serve, and healthcare professionals continue to place their trust in us. We take that really seriously, so thanks again for that. and thank you all for joining us. Have a great day.

This will conclude today's conference. We may disconnect your lines at this time. We thank you for your participation.